Viking Therapeutics (VKTX) saw a 5.46% rebound on Wednesday after a 42% decline due to a weight loss clinical trial with high dropout rates from adverse effects like nausea. CEO Brian Lian stated that GI-related adverse events could be reduced with lower doses. VKTX plans to explore this in an upcoming maintenance dosing study. While VKTX shows investment potential, AI stocks may offer higher returns with limited downside risk. For an inexpensive AI stock benefitting from Trump tariffs and onshoring, check out our free report on the best short-term AI stock.

Read more at Yahoo Finance: Viking Therapeutics (VKTX) Rebounds on Bargain-Hunting. Are You Missing Out?